Clinical trials: Cholera Vaccination, open to volunteers
Cholera Vaccination
Age-descending Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Adults and Children
This phase II study is intended to determine the immunogenicity and safety of single dose and two doses of OSP:rTTHc cholera conjugate vaccine (CCV) with or without alum adjuvant.
- Trial name
- NCT07509047
- Testing
- OSP:rTTHc CCV 25 ㎍ with Aluminum phosphate, OSP:rTTHc CCV 25 ㎍ without Aluminum phosphate, Euvichol®-Plus
- Where
- Kenya
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Cholera Vaccination Reaction
Safety and Immunogenicity Study of the DuoChol Oral Cholera Vaccine in Healthy Participants
The goal of this phase I, open-label, randomized, active-controlled Trial is to evaluate the safety and immunogenicity of the DuoChol Oral Cholera Vaccine in 18 to 45 years old healthy participants in Sweden.
- Trial name
- DuoChol (NCT07270796)
- Testing
- DuoChol, Dukoral®
- Where
- Sweden
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Cholera Vaccination Reaction
Phase 1b Ascending Dose Study of PanChol in Healthy Volunteers
Cholera is a serious diarrheal disease that can be fatal within hours of onset. The current available cholera vaccines to prevent the disease are not very effective.
- Trial name
- PanChol (NCT07107516)
- Testing
- PanChol
- Where
- Zambia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Cholera Vaccination
Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya
Background: Despite efforts to control cholera, outbreaks continue to occur in Kenya. Oral cholera vaccines (OCVs) are a critical tool in cholera prevention strategies.
- Trial name
- NCT07487077
- Testing
- Euvichol-S Oral Cholera Vaccine
- Where
- Kenya
- Volunteers
- 1,071 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Cholera Vaccination
Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus
This Phase I/III clinical trial is intended to establish the immunogenicity and safety profile of Biovac OCV-S compared to available WHO pre-qualified vaccine Euvichol®-Plus in healthy adults and children and in adult people…
- Trial name
- NCT07304284
- Testing
- Experimental: Biovac OCV-S (inactivated whole-cell monovalent (O1) oral cholera vaccine), Active Comparator, Euvichol®-Plus
- Where
- 5 sites in South Africa
- Volunteers
- 2,824 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Cholera
Impact Study of Cholera Vaccination in Endemic Areas - Clinical Surveillance
This project aims to fill this essential knowledge gap by assessing the impact of oral cholera vaccine mass campaigns in 2 sites (urban and rural) in DRC, described in this protocol.
- Trial name
- NCT04853186
- Where
- Democratic Republic of the Congo
- Volunteers
- 6,000 people
- Sponsor
- Epicentre
Typhoid and/or Cholera Vaccination
CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera
This is an open-label, non-randomized study. The purpose of this study is to better understand how vaccines against typhoid fever and cholera affect the normal immune system and bacteria in the intestine.
- Trial name
- NCT03705585
- Testing
- Vivotif Typhoid Oral Vaccine, Vaxchora
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore